drugset / Trial / NCT00206648
An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to determine the difference in preventing a relapse between Betaseron and Avonex. Patients with RRMS currently treated with Avonex will be randomized into 2 equal-size arms; one arm will continue on the standard dose of Avonex; one arm will be converted to Betaseron standard dose.
Timeline
- Start
- 2003-03
- Primary completion
- —
- Completion
- 2005-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Interferon beta-1a | Protein / enzyme biologic | 30 ug | Intramuscular |
| Comparator | Interferon beta-1b | Protein / enzyme biologic | 250 ug | Subcutaneous |